A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Status:
Terminated
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
Endothelin is a human hormone which has been associated with increased portal pressure in
patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the
effects of endothelin. The purpose of this study is to evaluate the effect of ambrisentan on
portal pressure and renal function in patients with advanced liver cirrhosis and with portal
hypertension. In this study, portal pressure will be determined at multiple times with the
aid of a catheter inserted into the body of the patient. The effect of ambrisentan on the
function of the kidney will also be investigated. This study will also evaluate the
concentrations of ambrisentan in blood in patients with liver cirrhosis.